S. Gopalakrishnan

发表

Mathematical modelling of host-disease-drug interactions in HIV disease

S. Gopalakrishnan, 2016 .

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

S. Gopalakrishnan, A. Othman, M. Mohamed, 2020, Journal of clinical pharmacology.

Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

S. Gopalakrishnan, A. Salem, K. Freise, 2018, Leukemia & lymphoma.

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial.

J. Novak, J. Bergeron, C. Dinardo, 2020, Blood.

Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy

B. Smith, A. Wei, S. Gopalakrishnan, 2020, Hematological oncology.

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies

K. Venkatakrishnan, J. Bolleddula, S. Gopalakrishnan, 2022, Clinical and translational science.

Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia

S. Gopalakrishnan, W. Wierda, A. Salem, 2020, Clinical pharmacology and therapeutics.

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis

S. Gopalakrishnan, A. Salem, S. Agarwal, 2019, Hematological oncology.

Estimating HIV-1 Fitness Characteristics from Cross-Sectional Genotype Data

Niko Beerenwinkel, Wilhelm Huisinga, Hesam Montazeri, 2014, PLoS Comput. Biol..

Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection

Amit Khatri, S. Gopalakrishnan, R. Menon, 2016, Clinical Pharmacokinetics.

Exposure–Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study

S. Gopalakrishnan, R. Redman, R. Menon, 2016, Advances in Therapy.

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials

S. Gopalakrishnan, M. Mohamed, E. Muensterman, 2021, Clinical and translational science.

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies

S. Gopalakrishnan, R. Menon, S. Mensing, 2018, Clinical Pharmacokinetics.

Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis

S. Gopalakrishnan, A. Salem, S. Mensing, 2019, Clinical and translational science.

Estimating HIV-1 Fitness Characteristics from Cross-Sectional Genotype Data

W. Huisinga, N. Beerenwinkel, Hesam Montazeri, 2014, PLoS Comput. Biol..

Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety

S. Gopalakrishnan, A. Salem, R. Menon, 2023, Hematological oncology.

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

S. Stilgenbauer, A. Kater, S. Gopalakrishnan, 2023, HemaSphere.

Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial

Ö. Yalkinoglu, S. Gopalakrishnan, Karthik Venkatakrishnan, 2024, Clinical pharmacology and therapeutics.

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

F. Dahlke, S. Gopalakrishnan, B. Cree, 2024, The Lancet Neurology.